Soft mist inhaler developer Resyca, a joint venture of Medspray Pharma and Recipharm, has announced the promotion of current Head of Development and Project Management Nicolas Buchmann to Chief Technical Officer. Buchman will take over from Wilbur de Kruijf, who is leaving to serve as CEO of a start-up inhaled drug developer called Thaerapy. Resyca also announced that Thaerapy has signed a licensing deal for use of Resyca’s SMI for delivery of a therapy for the treatment of pulmonary arterial hypertension (PAH).
The company did not disclose the value of the agreement with Thaerapy but said that the deal includes a signing milestone, future milestones, and a royalty on any future net sales. In addition to providing SMI devices, Resyca will provide Thaerapy with regulatory assistance and compounding, filling, and finishing services.
Resyca General Manager and Chief Operating Officer Bernhard Müllinger commented, “Nicolas will lead our technical team and drive continued innovation and growth at Resyca. With his expertise and our commitment to quality and customer satisfaction, we are well-positioned to continue providing innovative solutions to the pharmaceutical industry.”
Müllinger added, “We are thrilled to continue our collaboration with Wilbur as a valued customer of Resyca. We believe his new venture will further showcase the effectiveness of our inhaler technology and help us to advance our mission of providing patients with innovative and effective treatment options. We are grateful to Wilbur for his support and immense dedication to Resyca, which has contributed to the successful development of our inhalers and the establishment of our current customer base.”
de Kruijf said, “We are excited to be partnering with Resyca, a company with a proven track record of delivering high-quality and innovative inhaler technology. With Resyca’s support and expertise, we are well-positioned to advance our mission of bringing innovative and life-changing treatments to PAH patients.”
The Resyca inhalers are based on prefilled syringes, and earlier this year, the Stevanato Group announced that it would be supplying syringes for use in the SMI.
Read the Resyca press release on personnel changes.
Read the Resyca press release on the deal with Thaerapy.
